Results 121 to 130 of about 67,769 (290)

Allergen-specific basophil reactivity exhibits daily variations in seasonal allergic rhinitis

open access: yesAllergy. European Journal of Allergy and Clinical Immunology, 2014
It remains poorly understood how symptoms in allergic rhinitis are most severe during overnight or early in the morning. The circadian clock consisting of a network of several ‘clock genes’ including Clock drives daily rhythms in physiology.
N. Ando   +6 more
semanticscholar   +1 more source

Gut Microbiome Alterations by Allergen Sensitisation and Symptom Severity in Paediatric Allergic Rhinitis

open access: yes
Allergy, EarlyView.
Kunio Miyake   +7 more
wiley   +1 more source

Effectiveness and Predictors of House Dust Mite Subcutaneous Immunotherapy in Polysensitised Patients With Allergic Rhinitis: A Multicentre Retrospective Study

open access: yesClinical &Experimental Allergy, EarlyView.
Single‐allergen dust mite subcutaneous immunotherapy achieved 68.8% perennial symptom response rate in polysensitised allergic rhinitis patients. High mould and dust mite sIgE levels predicted poor allergen immunotherapy response, which indicated allergen‐specific sIgE levels may help guide personalised allergen immunotherapy decisions.
Zhouxian Pan   +13 more
wiley   +1 more source

Questionnaire Survey on Loquat‐Induced Oral Allergy Syndrome in School Children in Yamanashi, Japan

open access: yes
Allergy, EarlyView.
Ayumi Shimamura   +5 more
wiley   +1 more source

Regional variations and temporal trends of atopic diseases in Germany

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Prevalence rates of atopic diseases (atopic dermatitis [AD], allergic asthma [AA], and allergic rhinoconjunctivitis [ARC]) have increased in Germany. However, there is a lack of simultaneous consideration and of precise data on the spatiotemporal variation of these diseases.
Marie Sander   +4 more
wiley   +1 more source

Efficacy and Safety of Anti‐IL‐4Rα Stapokibart in Elderly Patients With Moderate‐To‐Severe Atopic Dermatitis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Background Elderly patients with moderate‐to‐severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti‐interleukin‐4 receptor α subunit (IL‐4Rα) monoclonal antibody, in different age subgroups.
Yan Zhao   +26 more
wiley   +1 more source

Antigen-Specific Immunotherapy against Allergic Rhinitis: The State of the Art

open access: yesAllergology International, 2010
Allergic rhinitis is the most prevalent type I allergy in industrialized countries. Pollen scattering from trees or grasses often induces seasonal allergic rhinitis, which is known as pollinosis or hay fever. The causative pollen differs across different
Takashi Fujimura, Yoshitaka Okamoto
doaj   +1 more source

Allergic Rhinitis: Treatment of a Seasonal problem [PDF]

open access: yes, 2015
Allergic rhinitis affects up to 30% of the population yet there is evidence that it is under treated and misdiagnosed. Allergy symptoms closely mimic other common illnesses and most medication used to treat seasonal allergies is now available over the ...
Whittier, John
core   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 782-790, March 2026.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy